Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens. - Wikidata - wikimedia - TriplyDB

Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens.

Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens.

http://www.wikidata.org/entity/Q33636347

about

Activity of and effect of subcutaneous treatment with the broad-spectrum antiviral lectin griffithsin in two laboratory rodent models The HIV glycan shield as a target for broadly neutralizing antibodies Recent strategies targeting HIV glycans in vaccine design A Blueprint for HIV Vaccine Discovery Designing synthetic vaccines for HIV Antibodies in HIV-1 vaccine development and therapy Structural Insights into the Anti-HIV Activity of the Oscillatoria agardhii Agglutinin Homolog Lectin Family Structural Basis of the Anti-HIV Activity of the Cyanobacterial Oscillatoria Agardhii Agglutinin Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies Viral Escape from Neutralizing Antibodies in Early Subtype A HIV-1 Infection Drives an Increase in Autologous Neutralization Breadth Broadly Neutralizing Antibody PGT121 Allosterically Modulates CD4 Binding via Recognition of the HIV-1 gp120 V3 Base and Multiple Surrounding Glycans Structural basis for diverse N-glycan recognition by HIV-1–neutralizing V1–V2–directed antibody PG16 Targeting host-derived glycans on enveloped viruses for antibody-based vaccine design HIV-1 gp120 as a therapeutic target: navigating a moving labyrinth Structural Constraints Determine the Glycosylation of HIV-1 Envelope Trimers Cell- and Protein-Directed Glycosylation of Native Cleaved HIV-1 Envelope Glycan clustering stabilizes the mannose patch of HIV-1 and preserves vulnerability to broadly neutralizing antibodies Glycans, galectins, and HIV-1 infection Pharmacokinetics of the Antiviral Lectin Griffithsin Administered by Different Routes Indicates Multiple Potential Uses Allosteric modulation of the HIV-1 gp120-gp41 association site by adjacent gp120 variable region 1 (V1) N-glycans linked to neutralization sensitivity Anti-Retroviral Lectins Have Modest Effects on Adherence of Trichomonas vaginalis to Epithelial Cells In Vitro and on Recovery of Tritrichomonas foetus in a Mouse Vaginal Model Structure of 2G12 Fab2 in complex with soluble and fully glycosylated HIV-1 Env by negative-stain single-particle electron microscopy Human milk oligosaccharides: every baby needs a sugar mama Investigation of griffithsin's interactions with human cells confirms its outstanding safety and efficacy profile as a microbicide candidate Composition and Antigenic Effects of Individual Glycan Sites of a Trimeric HIV-1 Envelope Glycoprotein Structural plasticity of the Semliki Forest virus glycome upon interspecies transmission.HIV-1 Glycan Density Drives the Persistence of the Mannose Patch within an Infected Individual.Dynamic electrophoretic fingerprinting of the HIV-1 envelope glycoprotein.DC-SIGN increases the affinity of HIV-1 envelope glycoprotein interaction with CD4.MALDI-MS/MS with traveling wave ion mobility for the structural analysis of N-linked glycans.Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates The genotype of early-transmitting HIV gp120s promotes α (4) β(7)-reactivity, revealing α (4) β(7) +/CD4+ T cells as key targets in mucosal transmission.Synthetic carbohydrate antigens for HIV vaccine design.Isolation of a monoclonal antibody that targets the alpha-2 helix of gp120 and represents the initial autologous neutralizing-antibody response in an HIV-1 subtype C-infected individual.Glycan-protein interactions in viral pathogenesis HIV-1 envelope proteins and V1/V2 domain scaffolds with mannose-5 to improve the magnitude and quality of protective antibody responses to HIV-1 Selection of a synthetic glycan oligomer from a library of DNA-templated fragments against DC-SIGN and inhibition of HIV gp120 binding to dendritic cells.The glycan shield of HIV is predominantly oligomannose independently of production system or viral clade.Differential glycosylation of envelope gp120 is associated with differential recognition of HIV-1 by virus-specific antibodies and cell infection.Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections

P2860

Q24610025-8A9A109C-EA99-43A7-9C05-8D90FB98C666 Q26786540-A26F805A-75BA-4D87-90F8-744DCA32E4FC Q26823603-B33E3F85-7147-4D96-A2A3-8C304AFB8D25 Q26829865-BDFF49AC-5D71-4123-9A09-0384AE9F9927 Q26862617-7214227A-D5C1-421F-A001-8B33911550C2 Q27011574-CB40C09F-572E-4028-A633-6E2DF596D975 Q27671174-F938D46F-74AC-470D-8DE9-1DB1F2F65AF9 Q27671641-1C7638FA-4371-4613-BC3B-9B46AD71891A Q27674878-12534E0A-77AE-482E-94AC-92D1A972873D Q27676728-2671015C-A79A-460E-85D4-CCAC86183FEA Q27678062-964229D0-F07D-455B-8DBC-6242BFAB2C6F Q27678312-57552414-ADA4-460F-8FDD-A7699F3385E6 Q28084672-A83B2004-5F1F-4ECB-8882-6C032B77B76E Q28086826-5C158638-AA70-4C6D-BA08-B8AECC75B6F4 Q28263063-8F52D59C-85DB-48A8-99BB-DE03A3B44F9C Q28263655-33A44458-CB9D-4C06-85EE-44776A30672E Q28263932-56897D1C-B48C-4992-B861-362A3900018F Q28265115-8ED752A8-DE47-4BC9-A242-2B37BDF1E091 Q28354743-867B24ED-0387-4D98-BA41-6FB752618800 Q28485983-D110BBFE-715D-4B88-A65C-7D70376E2C3B Q28547132-84A659CF-2E7B-4A83-AEB6-40D9B85DF040 Q28654490-C5878B3A-DB7F-46E9-B7A6-1FD03D8C20C5 Q28728728-5D1A681C-FB66-4325-9065-B9F7D843F04D Q28741890-F8EBD31C-94BC-4936-814F-06563E1D6AE1 Q29306052-4224F437-2075-48F3-B887-CAA2389C943B Q30358358-291925A9-ADCA-4965-8F01-768A07A1780E Q30393763-C823E9EE-4ADD-4FE3-A9FE-542A772A380E Q30454762-7AD78C87-A480-4E8A-B15B-3B65F244697B Q30472149-6444E326-9D0D-48B2-B2E3-3593D33ADF4A Q31095515-50522C41-0D36-412E-89B8-E7C4A5E872D2 Q33612459-044E8DD2-6705-492A-9704-5AC8309F1E70 Q33839456-C9AE163D-D3EC-4ED1-8EBC-AC6D84920975 Q33909079-E7CE1535-06D0-4E1F-8DE8-499C7F6B66C4 Q33912373-D41245E2-14E3-4753-B98E-E349AAEAC5E9 Q33926161-208173A0-F8EF-442A-9928-C2B56BFB63C9 Q33947008-71FCDD0E-5FF1-4C7F-961B-869946BD2CBC Q33970022-8933F4C1-947A-423C-9FB2-85B442ABA2DA Q33999756-7C8AB350-1531-49EE-8FCC-AFE24318EAF5 Q34034659-50BE9BD6-9F1B-42F1-8C0A-DC31A0126DC3 Q34042642-3B08D623-8F6B-4D63-B9A3-864BC2D1B5A2

P2860

Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens.

http://www.wikidata.org/entity/Q33636347

description

2010 nî lūn-bûn

@nan

2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens.

@ast

Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens.

@en

type

label

Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens.

@ast

Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens.

@en

prefLabel

Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens.

@ast

Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens.

@en

P1433

Q33636347-ECBAA46A-5E45-4D88-B53A-CC5E48C9469A

P1476

Q33636347-55F1B3F8-6E49-41A6-AB34-AD1E2713DE2F

P2093

Q33636347-0174FADA-3D53-485A-9362-CCF150015B4A

Q33636347-2FD4CBC1-FDB8-4BB5-B6C6-627606112494

Q33636347-514F451C-E7C0-416D-8A50-06BD0AE719BE

Q33636347-68AB5E24-BE39-4B88-9476-8B7BD553EAA8

Q33636347-7561C66E-35DC-417B-BF36-1AF45B09CC3E

Q33636347-EC12C380-A225-4CFE-AB33-7391A3FDC3C8

P2860

Q33636347-04348DB3-D52A-4C52-869F-5CAAECFB2310

Q33636347-0715E242-5876-40FE-8F3B-BC3BAC5E9A2A

Q33636347-127D38AF-D72A-4730-B2EC-9033AEE91C8C

Q33636347-16CBEFE5-52B7-477E-A34B-42F38202DA6F

Q33636347-229A1C1C-CBFC-4FE8-8EA4-F3511E3735D7

Q33636347-22D71992-1642-412E-A17D-66F7F8736FA8

Q33636347-2604CB7F-78FA-48B4-9221-B7877501EF02

Q33636347-2B9D0CF2-05E1-4328-A6D2-ED49DFF52A49

Q33636347-2BA2DCC3-E3EC-489E-87C0-CD5EE4F12F14

Q33636347-2EA88CE3-B905-487F-9F44-048B2C10E23A

P304

Q33636347-110DFB62-8753-4668-A799-0D65E4DCA8EC

P31

Q33636347-6E446613-D97D-433B-97A9-04D55615B5B6

P356

Q33636347-59BD0A83-9323-42CF-854D-168750393F34

P407

Q33636347-EDCF7766-3138-4FB2-B155-82B890864FC3

P433

Q33636347-F75190E5-6F4B-4819-AB23-AF76FEB60B26

P478

Q33636347-78CD43B0-566A-4E43-896E-27ACDBC9985F

P50

Q33636347-46D11A56-98F5-4E0E-9D3D-AC95D9D8B8E1

Q33636347-8C458264-8B70-4BB1-B6FB-3F3DA19323B9

P577

Q33636347-EF8F4BD2-E84B-4B4B-AEE9-57CF7DDC7557

P5875

Q33636347-AD8A8403-7907-4A65-B498-4F8B662EBC68

P698

Q33636347-F63B620D-63B3-48B6-AF29-5AC65696B9D1

P932

Q33636347-4D46B3D8-9AD7-4343-A32C-FD3A7318E35A

P356

PNAS.1006498107

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens

@en

P2093

Camille Bonomelli

http://www.w3.org/2001/XMLSchema#string

Christopher N Scanlan

http://www.w3.org/2001/XMLSchema#string

David J Harvey

http://www.w3.org/2001/XMLSchema#string

Dennis R Burton

http://www.w3.org/2001/XMLSchema#string

Raymond A Dwek

http://www.w3.org/2001/XMLSchema#string

Snezana Vasiljevic

http://www.w3.org/2001/XMLSchema#string

P2860

Mass spectrometric characterization of glycosylation of hepatitis C virus E2 envelope glycoprotein reveals extended microheterogeneity of N-glycans

Structural Basis of Immune Evasion at the Site of CD4 Attachment on HIV-1 gp120

Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility

Assembly of asparagine-linked oligosaccharides

DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells

GP120: target for neutralizing HIV-1 antibodies

Alpha-(1-3)- and alpha-(1-6)-D-mannose-specific plant lectins are markedly inhibitory to human immunodeficiency virus and cytomegalovirus infections in vitro

Antibody neutralization and escape by HIV-1

Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

P304

13800-13805

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1006498107

http://www.w3.org/2001/XMLSchema#string

P407

P433

31

http://www.w3.org/2001/XMLSchema#string

P478

107

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-07-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45275107

http://www.w3.org/2001/XMLSchema#string

P698

20643940

http://www.w3.org/2001/XMLSchema#string

P932

2922250

http://www.w3.org/2001/XMLSchema#string